Get the Stockscreener App
13.00
0.24%
-0.00
4 D Molecular Therapeutics Inc stock is traded at $13.00, with a volume of 248.15K.
It is down -0.24% in the last 24 hours and up +50.11% over the past month.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
See More
Previous Close:
$13.00
Open:
$13
24h Volume:
248.15K
Relative Volume:
0.29
Market Cap:
$677.76M
Revenue:
$88.24M
Net Income/Loss:
$-160.90M
P/E Ratio:
-4.8795
EPS:
-2.6642
Net Cash Flow:
$-129.35M
1W Performance:
+0.69%
1M Performance:
+50.11%
6M Performance:
+80.38%
1Y Performance:
+205.88%
1-Day Range:
$12.73
$13.20
1-Week Range:
$12.57
$14.00
52-Week Range:
$3.86
$14.00
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
12.96 | 695.27M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Nov-07-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Form 144 4D Molecular Therapeutics For: 30 June By Investing.com - Investing.com Canada
FDMT4D Molecular Therapeutics Inc Latest SEC Filings - Finviz
FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720 - Stock Titan
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists - The Manila Times
4DMT to present 2-year PRISM trial follow-up at retina meeting - Stock Titan
H.C. Wainwright reiterates Buy on 4D Molecular stock on trial progress By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
4D Molecular Therapeutics secures $200M credit facility - Investing.com
4D Molecular (FDMT) Completes Enrollment for Phase 3 Clinical Tr - GuruFocus
4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd - marketscreener.com
4D Molecular Therapeutics Secures Strategic Credit Facility for Up to $200 Million from Hercules Capital - marketscreener.com
4D Molecular Therapeutics Secures $200 Million Loan Facility - TipRanks
4D Molecular Therapeutics Secures Up to $200 Million Term Loan Facility From Hercules Capital - TradingView
4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules - Stock Titan
4DMT gets $20M now, with up to $200M in debt support - Stock Titan
4D Molecular Therapeutics, Inc. Actuals & Estimates (NASDAQ:FDMT) - TradingView
Strength seen in 4D Molecular Therapeutics (FDMT): Can its 7.9% jump turn into more strength? - MSN
4d molecular therapeutics CLO Scott Bizily sells $117,720 in stock - Investing.com UK
Form 4 4D Molecular Therapeutics Inc For: 25 June By Investing.com - Investing.com Nigeria
4d molecular therapeutics CLO Scott Bizily sells $117,720 in stock By Investing.com - Investing.com Australia
4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12 - Stock Titan
FDMT Forecast — Price Target — Prediction for 2027 - TradingView
Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap - Barchart.com
Form 144 4D Molecular Therapeutics For: 23 June By Investing.com - Investing.com South Africa
4d molecular therapeutics CEO David Kirn sells $1.2m in stock - Investing.com UK
4d molecular therapeutics CEO David Kirn sells $1.2m in stock By Investing.com - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Insider Sell Alert: David Kirn Sells 114,746 Shares of 4D Molecu - GuruFocus
[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares - Stock Titan
4D Molecular Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kirn David - Moomoo
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Yahoo Finance
Form 144 4D Molecular Therapeutics For: 22 June By Investing.com - Investing.com Nigeria
David Kirn reports sale of 1,922 FDMT shares via Goldman Sachs (FDMT) - Stock Titan
4D Molecular Therapeutics Stockholders Back Directors and Governance - TipRanks
4D Molecular Therapeutics stockholders elect directors and approve proposals at annual meeting - Investing.com Australia
Form 8K 4D Molecular Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics (NASDAQ: FDMT) investors approve directors, auditor and pay - Stock Titan
4D Molecular Therapeutics (FDMT) AGM 2026 Summary - Quartr
4D Molecular Therapeutics (FDMT) Rallies 2.55% as Stock Tests Key Resistance Near $10.14Put Flow Alert - dars.gov.et
4D Molecular Therapeutics (FDMT) director granted 50,000 stock options with CIC vesting - Stock Titan
4D Molecular (NASDAQ: FDMT) grants director 50,000 stock options - Stock Titan
4D Molecular Therapeutics (FDMT) director receives 50,000-share stock option grant - Stock Titan
4D Molecular (NASDAQ: FDMT) director gets 50,000 stock options grant - Stock Titan
4D Molecular Therapeutics (FDMT) grants director John F. Milligan 75,000 options - Stock Titan
4D Molecular (FDMT) grants director 50,000 stock options at $9.42 - Stock Titan
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4 D Molecular Therapeutics Inc Stock (FDMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer |
Jun 23 '26 |
Option Exercise |
4.14 |
9,810 |
40,613 |
18,427 |
| Bizily Scott | Chief Legal Officer |
Jun 23 '26 |
Sale |
12.00 |
9,810 |
117,720 |
8,617 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):